ATE298371T1 - Nicht-primaten lentivirale vektoren und verpackungssysteme - Google Patents

Nicht-primaten lentivirale vektoren und verpackungssysteme

Info

Publication number
ATE298371T1
ATE298371T1 AT98948216T AT98948216T ATE298371T1 AT E298371 T1 ATE298371 T1 AT E298371T1 AT 98948216 T AT98948216 T AT 98948216T AT 98948216 T AT98948216 T AT 98948216T AT E298371 T1 ATE298371 T1 AT E298371T1
Authority
AT
Austria
Prior art keywords
cells
packaging
vectors
lentiviral vectors
primate lentiviral
Prior art date
Application number
AT98948216T
Other languages
English (en)
Inventor
Eric M Poeschia
David J Looney
Flossie Wong-Staal
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE298371T1 publication Critical patent/ATE298371T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Auxiliary Devices For And Details Of Packaging Control (AREA)
  • Laminated Bodies (AREA)
  • Adhesive Tapes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Wrappers (AREA)
AT98948216T 1997-09-24 1998-09-15 Nicht-primaten lentivirale vektoren und verpackungssysteme ATE298371T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93663397A 1997-09-24 1997-09-24
PCT/US1998/019162 WO1999015641A1 (en) 1997-09-24 1998-09-15 Non-primate lentiviral vectors and packaging systems

Publications (1)

Publication Number Publication Date
ATE298371T1 true ATE298371T1 (de) 2005-07-15

Family

ID=25468901

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98948216T ATE298371T1 (de) 1997-09-24 1998-09-15 Nicht-primaten lentivirale vektoren und verpackungssysteme

Country Status (9)

Country Link
US (2) US6555107B2 (de)
EP (1) EP1017797B1 (de)
JP (1) JP2001517433A (de)
AT (1) ATE298371T1 (de)
AU (1) AU747438B2 (de)
CA (1) CA2304983A1 (de)
DE (1) DE69830663T2 (de)
ES (1) ES2245042T3 (de)
WO (1) WO1999015641A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
WO1999032646A1 (en) * 1997-12-22 1999-07-01 Oxford Biomedica (Uk) Limited Equine infectious anaemia virus (eiav) based
GB2356200B (en) * 1997-12-22 2002-05-01 Oxford Biomedica Ltd Retroviral vectors
CA2318575A1 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6730297B1 (en) 1999-05-28 2004-05-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing lysosomal storage disorders
JP2003512829A (ja) 1999-10-22 2003-04-08 アヴェンティス パストゥール リミテッド 改変型ｇｐ１００およびその使用
EP1103615A1 (de) * 1999-11-25 2001-05-30 Universite De Geneve Vektoren, die nicht-teilende Zellen immortalisieren können und Zellen, die mit diesen Vektoren immortalisiert wurden
US6864085B2 (en) 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
EP1238092B1 (de) * 1999-12-14 2007-01-24 Novartis AG Auf dem rinderimmunschwächevirus (biv) basierte vektoren
US6656706B2 (en) 1999-12-23 2003-12-02 The United States Of America As Represented By The Department Of Health And Human Services Molecular clones with mutated HIV gag/pol, SIV gag and SIV env genes
CA2408328C (en) * 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US6767699B2 (en) 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
US6712612B1 (en) 2000-12-12 2004-03-30 Genecure Llc Safe and stable retroviral helper cell line and related compositions and methods
WO2002067971A2 (en) 2001-02-22 2002-09-06 Novartis Ag Use of endostatin in the treatment of ocular neovascularization
BR0214275A (pt) 2001-11-19 2004-09-21 Scil Technology Gmbh Dispositivo tendo propriedades osteocondutora e osteoindutora
JP2005533485A (ja) * 2002-02-04 2005-11-10 ノバルティス アクチエンゲゼルシャフト 組換えウシ免疫不全ウイルスに基づく遺伝子導入システム
EP1864691B1 (de) 2002-04-09 2011-07-20 Sanofi Pasteur Limited Modifizierte CEA-Nukleinsäure und entsprechende Expressionsvektoren
DE60332122D1 (de) * 2002-08-28 2010-05-27 Novartis Ag Gentherapie des auges
WO2004024199A1 (en) * 2002-09-10 2004-03-25 Scil Technology Gmbh Metal implant coated under reduced oxygen concentration with osteoinductive protein
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
ATE506444T1 (de) * 2003-10-08 2011-05-15 Sanofi Pasteur Ltd Modifizierter cea/b7-vektor
US7135339B2 (en) * 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
US7196062B2 (en) 2004-02-18 2007-03-27 Wisconsin Alumni Research Foundation Method for treating glaucoma
WO2005079829A2 (en) * 2004-02-18 2005-09-01 Wisconsin Alumni Research Foundation Method for treating glaucoma
US20060199266A1 (en) * 2004-08-12 2006-09-07 Vectorcore A Co., Ltd. CAEV-based vector systems
MX2007010008A (es) 2005-02-16 2008-01-18 Lentigen Corp Vectores lentivirales y su uso.
US20070092883A1 (en) * 2005-10-26 2007-04-26 De Luwe Hoek Octrooien B.V. Methylation specific multiplex ligation-dependent probe amplification (MS-MLPA)
CN105586358B (zh) * 2007-05-29 2020-08-25 克里斯多佛·B·里德 专能细胞群的生产和使用方法
US11859168B2 (en) 2007-05-29 2024-01-02 Christopher B. REID Electroporation, developmentally-activated cells, pluripotent-like cells, cell reprogramming and regenerative medicine
EP2215231A4 (de) 2007-10-15 2010-12-01 Univ Queensland Expressionssystem zur modulation einer immunantwort
WO2009065080A1 (en) 2007-11-16 2009-05-22 San Diego State University Research Foundation Compositions and method for manipulating pim-1 activity in circulatory system cells
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
US9730996B2 (en) 2012-10-24 2017-08-15 Texas Biomedical Research Institute Involucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
WO2015066796A1 (en) * 2013-11-06 2015-05-14 Nexen Energy Ulc Processes for producing hydrocarbons from a reservoir
EP2871233A1 (de) 2013-11-12 2015-05-13 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur Herstellung von biogenen Stoffen
KR102895580B1 (ko) 2015-12-09 2025-12-03 진강 메디신 (오스트레일리아) 피티와이 엘티디 치료를 위한 면역조절용 조성물
WO2018018082A1 (en) 2016-07-26 2018-02-01 The Australian National University Immunostimulatory compositions and uses therefor
TWI820034B (zh) 2017-07-31 2023-11-01 香港商映像生物有限公司 眼部疾病之細胞模式及用於眼部疾病的療法
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
DE102023102366A1 (de) 2023-01-31 2024-08-01 BRANDENBURGISCHE TECHNISCHE UNIVERSITÄT COTTBUS-SENFTENBERG, Körperschaft des öffentlichen Rechts Testsystem aufweisend stabil CYP-transfizierte oder transduzierte Säugetierzellen

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
AU625013B2 (en) 1989-11-03 1992-06-25 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
JPH06510181A (ja) 1991-05-29 1994-11-17 アメリカ合衆国 Ｒｎａプロセシングの調節機能を備えた真核細胞発現ベクター
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
PT702723E (pt) 1993-04-21 2003-01-31 Pasteur Institut Implante biocompativel para a expressao e a secrecao in vivo de um composto terapeutico
US5670361A (en) 1993-05-17 1997-09-23 The Regents Of The University Of California HIV-specific ribozymes
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
WO1995025547A1 (en) 1994-03-24 1995-09-28 University Of Washington Devices and methods for implanting transduced cells
WO1995025806A2 (en) * 1994-03-24 1995-09-28 Syngenix Limited Packaging-deficient lentiviruses
AU2419595A (en) 1994-05-10 1995-11-29 Hisamitsu Pharmaceutical Co., Inc. Recombinant human immunodeficiency virus vector and process for producing the same
WO1995032300A1 (en) 1994-05-23 1995-11-30 University Of Medicine & Dentistry Of New Jersey Selective biological destruction of tumor cells
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
JP3908274B2 (ja) 1995-03-09 2007-04-25 ゲーエスエフ−フォルシュンクスツェントラム・フュア・ウムベルト・ウント・ゲズントハイト・ゲーエムベーハー 遺伝子治療用の抗菌ペプチドをコードする治療用遺伝子を有するベクター
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
GB9510272D0 (en) 1995-05-22 1995-07-19 Isis Innovation Retroviral vectors
GB9517263D0 (en) 1995-08-23 1995-10-25 Cancer Res Campaign Tech Expression systems
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
GB9525639D0 (en) * 1995-12-15 1996-02-14 Isis Innovation Improved retroviral vectors
CA2247091A1 (en) 1996-03-05 1997-09-12 The Regents Of The University Of California Recombinant live feline immunodeficiency virus and proviral dna vaccines
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
AU3212197A (en) 1996-06-20 1998-01-07 Salk Institute For Biological Studies, The Modular assembly retroviral vectors and uses thereof
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
CA2288328A1 (en) * 1997-05-13 1998-11-19 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2318575A1 (en) 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors

Also Published As

Publication number Publication date
US6555107B2 (en) 2003-04-29
JP2001517433A (ja) 2001-10-09
CA2304983A1 (en) 1999-04-01
ES2245042T3 (es) 2005-12-16
WO1999015641A1 (en) 1999-04-01
EP1017797A1 (de) 2000-07-12
US20010016347A1 (en) 2001-08-23
DE69830663D1 (de) 2005-07-28
EP1017797A4 (de) 2003-04-16
US20030012769A1 (en) 2003-01-16
DE69830663T2 (de) 2006-05-11
AU9483798A (en) 1999-04-12
AU747438B2 (en) 2002-05-16
EP1017797B1 (de) 2005-06-22

Similar Documents

Publication Publication Date Title
ATE298371T1 (de) Nicht-primaten lentivirale vektoren und verpackungssysteme
FI935174A0 (fi) Tumoeravstoetande antigenprekursorer, tumoeravstoetande antigener och anvaendning av dem
DE69636032D1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
CY1111504T1 (el) Αζαδικυκλοαλκανια ως ρυθμιστες του ccr5
CY1106216T1 (el) 5´ ESTs ΓΙΑ ΜΗ ΙΣΤΟ-ΕΙΔΙΚΕΣ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ
DE69516847D1 (de) Chlorpyrimidine als zwischenprodukte
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
GR1000850B (el) Διαλυτα ανθρωπινα τεμαχια cd4 και οι χρησεις τους.
DE60044754D1 (de) Trans-lentivirales Vektor System
CY1105398T1 (el) 5΄ ESTs ΓΙΑ ΕΚΚΡΙΤΙΚΕΣ ΠΡΩΤΕΪΝΕΣ ΠΟΥ ΕΚΦΡΑΖΟΝΤΑΙ ΣΕ ΔΙΑΦΟΡΟΥΣ ΙΣΤΟΥΣ
IL121272A0 (en) Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug
ATE361359T1 (de) Funktion und aktivität des viralen proteins r (vpr)
EP1070122A4 (de) Induktion apoptischer oder zytotoxischer genexpression durch adenovirus-vermittelten gen-kotransfer
DE69627644D1 (de) Vektoren, die therapeutische gene fuer antimikrobielle peptide enthalten, zur verwendung in der gentherapie
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
TR199901385T2 (xx) Piperidin t�revleri.
DK0697875T3 (da) Anvendelse af modificerede TALL-104 celler til behandling af cancer og virale sygdomme
BR9712767A (pt) Expressão especìfica para tecido de proteìna de retinoblastoma
HUP9900011A2 (hu) A GAX protein alkalmazása rák kezelésére
MX9700560A (es) Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.
CY1112243T1 (el) Θεραπευτικη αγωγη μολυνσεων ιου ηiv με οξειδωμενο δια υποχλωριωδους οξεος ανθρωπινο πλασμα αιματος
ATE292174T1 (de) Gentransfer in humane lymphocyten mittels retroviraler scfv-zelltargeting vektoren
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
WO2000017375A3 (en) Method to treat haemophilia by in vivo gene therapy with retroviral vectors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1017797

Country of ref document: EP

REN Ceased due to non-payment of the annual fee